Every Form 4 that Hims & Hers Health, Inc. (HIMS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow HIMS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HIMS filings page.
Hims & Hers Health, Inc. Chief Policy Officer Deborah M. Autor exercised restricted stock units that converted into 3,656 shares of Class A Common Stock on June 11, 2026 at no cost. These RSUs each represented a right to receive one share upon vesting. Following the transaction, she directly holds 31,438 Class A shares, and no shares were sold in this filing.
Hims & Hers Health, Inc. director Christopher D. Payne exercised restricted stock unit awards into a total of 14,343 shares of Class A Common Stock in June 2026, all at a price of $0.00 per share. These are compensation-related derivative exercises rather than open‑market purchases or sales.
After the transactions, he holds 34,318 shares directly and 110,000 shares indirectly through The Payne Family Trust dated September 17, 2020. Some RSUs remain outstanding, including 10,040 units granted in lieu of $14,875 of first‑quarter 2026 director and committee cash fees, calculated at a grant price of $22.98 per share and scheduled to vest on the company’s next quarterly vesting date.
Hims & Hers Health, Inc. director Christiane Pendarvis exercised previously granted Restricted Stock Units (RSUs), converting 3,656 RSUs into an equal number of Class A Common shares at a stated price of $0.00 per share. Following this transaction, she directly holds 55,430 Class A Common shares.
The RSUs represent a contingent right to receive one share of Class A Common Stock for each unit and will vest, subject to continuous service, on the earlier of the company’s 2026 annual meeting of stockholders or June 15, 2026. This is a compensation-related, non‑open‑market equity award rather than a market purchase or sale.
Hims & Hers Health, Inc. director Manuel Anja reported equity compensation activity involving Restricted Stock Units (RSUs) that convert into Class A Common Stock. On June 11, 2026, RSU vesting and exercise resulted in the acquisition of 3,656 shares of Class A Common Stock at a stated price of $0.0000 per share, increasing his direct holdings to 28,631 shares.
On June 15, 2026, additional RSUs were exercised for 10,040 shares of Class A Common Stock, again at a stated price of $0.0000 per share, bringing his direct ownership to 38,671 shares. The footnotes explain that each RSU is a contingent right to receive one share of Class A Common Stock, subject to continuous service and service-based vesting schedules through dates including June 15, 2025, June 15, 2026, and May 15, 2027.
Hims & Hers Health, Inc. director Delos M. Cosgrove reported a compensation-related equity transaction involving restricted stock units. On June 11, 2026, he exercised RSUs covering 3,656 shares of Class A Common Stock, converting them from derivative form into common shares.
Following this RSU conversion, Cosgrove directly holds 67,995 shares of Class A Common Stock. The RSUs represent a contingent right to receive one share of Class A Common Stock for each unit and, subject to continuous service, will vest on the earlier of the company’s 2026 annual stockholders’ meeting or June 15, 2026.
Hims & Hers Health, Inc. director David B. Wells reported an open-market purchase of Class A Common Stock. On May 26, 2026, he bought 48,400 shares at an average price of $24.235 per share, increasing his direct holdings to 224,417 shares.
The reported purchase price is a weighted average, with individual trades executed between $24.19 and $24.25 per share. Wells conducted these transactions as direct ownership in the company’s Class A Common Stock.
Hims & Hers Health, Inc. director and Chief Medical Officer Patrick Harrison received a grant of 435 Restricted Stock Units as part of his board compensation. The RSUs were issued in lieu of a $10,000 cash retainer for the first quarter of 2026 and convert into Class A Common Stock on vesting. The award will vest in full on the company’s next quarterly vesting date, giving him equity-based compensation instead of cash for that period.
Payne Christopher D reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. director Christopher D. Payne received a grant of 647 Restricted Stock Units as equity compensation. Each RSU represents a contingent right to receive one share of Class A common stock. The award was issued under the company’s Director Compensation Policy.
The RSUs were granted in lieu of $14,875 in director and committee cash fees for the first quarter of 2026, using a grant price of $22.98. All 647 RSUs will vest in full on the company’s next quarterly vesting date, leaving Payne with 647 RSUs reported as directly owned after this transaction.
WELLS DAVID B reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. director David B. Wells received a grant of 957 restricted stock units as part of his 2026 first-quarter board compensation. The RSUs were issued in lieu of $22,000 of cash retainer and committee fees, using a grant price of $22.98 per unit. Each RSU represents a contingent right to receive one share of Class A common stock and will vest in full on the company’s next quarterly vesting date. Following this compensation grant, Wells holds 957 RSUs directly.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe reported an option exercise and related share sale in Class A common stock. He exercised stock options to acquire 7,950 shares at $5.01 per share and sold 7,950 shares at an average price of $23.6372 per share.
Following these transactions, he held 262,954 shares directly and 7,853 shares indirectly through the Oluyemi Okupe Separate Property Trust dated September 1, 2021. The filing notes that the stock option exercises and sales were effected under a Rule 10b5-1 trading plan adopted on May 21, 2025, and that the stock options were fully vested and exercisable.
Hims & Hers Health, Inc. Chief Legal Officer Soleil Boughton sold 9,463 shares of Class A Common Stock in an open-market transaction at $30.00 per share. After the sale, Boughton directly holds 299,368 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person.
Hims & Hers Health Chief Financial Officer Oluyemi Okupe exercised stock options and sold shares of Class A Common Stock. On April 20, 2026, he exercised options for 7,000 shares at $11.53 and 5,553 shares at $5.01, acquiring a total of 12,553 shares. The same day, he completed an open-market sale of 19,645 shares at an average price of $29.9626, under a pre-arranged Rule 10b5-1 trading plan adopted on May 21, 2025. Following these transactions, he held 262,954 shares directly and 7,853 shares indirectly through the Oluyemi Okupe Separate Property Trust dated September 1, 2021. The filing notes the options exercised were fully vested, with some awards vesting monthly over four years beginning April 1, 2023.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe reported option exercises and share sales under a pre-arranged Rule 10b5-1 trading plan. On April 16–17, Okupe sold a total of 54,927 shares of Class A Common Stock in open-market transactions at average prices of $25.8964 and $27.8344. He also exercised stock options for 6,184 shares at an exercise price of $5.01 per share, converting derivative awards into common stock. Following these transactions, Okupe holds 270,046 shares directly and 7,853 shares indirectly through the Oluyemi Okupe Separate Property Trust, and retains stock options representing 129,403 shares expiring on February 23, 2032.
Hims & Hers Health, Inc. Chief Executive Officer Andrew Dudum reported a bona fide gift of a total of 845,866 shares of Class A Common Stock on April 9, 2026. The Form 4 shows two gift transactions of 422,933 shares each, recorded as non-derivative dispositions with no price paid.
After the gifts, Dudum holds 887,684 shares directly. He also has indirect holdings through several trusts, including 470,457 shares held by the Trustee of the Dudum Family Community Property Trust and additional blocks held in various Dudum family and GRAT trusts. These entries reflect estate and trust planning rather than open-market trading activity.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe exercised stock options and sold the resulting shares. He exercised options for 3,975 shares of Class A Common Stock at an exercise price of $5.01 per share, then sold 3,975 shares at an average price of $19.977 per share.
The option exercise and sale were made under a Rule 10b5-1 trading plan adopted on May 21, 2025. After these transactions, he holds 318,789 shares directly and 7,853 shares indirectly through the Oluyemi Okupe Separate Property Trust dated September 1, 2021.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe exercised stock options and sold shares in a pre-planned transaction. On March 20, 2026, he exercised options for 4,489 shares of Class A common stock at $5.01 per share and acquired the same number of shares.
That same day, he executed an open-market sale of 9,217 shares at an average price of $23.7677, with trades occurring between $23.73 and $23.92, under a Rule 10b5-1 trading plan adopted on May 21, 2025. After these transactions, he directly holds 318,789 shares and indirectly holds 7,853 shares through the Oluyemi Okupe Separate Property Trust dated September 1, 2021.
Hims & Hers Health, Inc. PAO Irene Becklund completed an open-market sale of 5,529 shares of Class A Common Stock at $24.69 per share. After this transaction, she directly holds 8,752 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2025, indicating it was scheduled in advance rather than timed discretionarily.
Hims & Hers Health, Inc. Chief Legal Officer Soleil Boughton executed an open-market sale of 4,812 shares of Class A common stock at $24.69 per share. After this transaction, she directly holds 308,831 shares. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025, indicating it was scheduled in advance rather than timed opportunistically.
Hims & Hers Health, Inc. Chief Operating Officer Michael Chi reported an open-market sale of 97,289 shares of Class A common stock on March 17, 2026 at an average price of $24.69 per share. After this transaction, he continues to hold 407,282 shares directly.
According to a footnote, this sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 4, 2025, which means the trades were scheduled in advance rather than timed discretionarily.
Hims & Hers Health, Inc. Chief Operating Officer Michael Chi reported compensation-related stock activity tied to restricted stock units (RSUs). On March 13, 2026, he converted vested RSUs into 72,108 shares of Class A common stock.
To satisfy tax withholding obligations on these vestings, the company withheld a total of 237,756 shares of Class A common stock at $24.77 per share, rather than selling shares on the open market. After all exercises and tax withholdings, Chi directly holds 504,571 shares of Class A common stock.
The RSUs are subject to service-based vesting over four-year periods, with quarterly vesting dates beginning on various schedules between June 15, 2022 and June 15, 2025.
Hims & Hers Health, Inc. director Christiane Pendarvis exercised previously granted restricted stock units, converting 15,211 RSUs into the same number of Class A common shares at a price of $0.00 per share, reflecting equity compensation rather than an open-market purchase.
The RSUs vest over three years, with one-third vesting on March 15, 2024, one-third on March 15, 2025, and one-third on March 15, 2026. Following this conversion, Pendarvis directly holds 51,774 Class A shares, and the filing shows no sales or tax-withholding disposals, indicating a straightforward exercise-and-hold event.
Hims & Hers Health, Inc. director and Chief Medical Officer Carroll Patrick Harrison reported the vesting and settlement of restricted stock units into Class A Common Stock. On March 13, 2026, RSU awards for 8,149, 4,840 and 3,533 units converted into a total of 16,522 Class A shares at a conversion price of $0.00.
To satisfy tax withholding obligations related to this RSU vesting, 4,022 Class A shares were withheld by the issuer at $24.77 per share, a non‑market, tax-withholding disposition rather than an open-market sale. Following these transactions, Harrison holds 182,440 Class A Common shares directly.
Hims & Hers Health, Inc. director and Chief Policy Officer Deborah M. Autor exercised and settled 32,919 Restricted Stock Units (RSUs) into the same number of Class A Common shares on March 13, 2026. Of these, 11,312 shares of Class A Common Stock, valued at $24.77 per share, were withheld by the company to cover tax withholding obligations related to the RSU vesting. Following these transactions, she directly owned 27,782 shares of Class A Common Stock, and 493,792 RSUs remained outstanding, each representing a contingent right to receive one share. The remaining RSUs are subject to service-based vesting in substantially equal quarterly installments on March 15, June 15, September 15 and December 15 over a four-year period, beginning on March 15, 2026.
Hims & Hers Health, Inc. principal accounting officer Irene Becklund exercised and settled multiple restricted stock unit (RSU) awards into 17,987 shares of Class A Common Stock on March 13, 2026. Each RSU converts into one share of Class A Common Stock.
To cover tax withholding obligations tied to these RSU vestings, 5,832 shares were withheld by the company at a price of $24.77 per share, a non-market, tax-related disposition rather than an open-market sale. Following these transactions, Becklund directly holds 14,281 shares of Class A Common Stock. The RSUs vest based on continued service over four-year schedules with quarterly vesting dates.
Hims & Hers Health, Inc. Chief Executive Officer Andrew Dudum reported the vesting and settlement of restricted stock units on March 13, 2026. The RSU conversions resulted in the acquisition of 164,369 shares of Class A common stock. To cover tax withholding obligations related to these RSUs and performance RSUs that vested on February 23, 2026, the issuer withheld a total of 526,486 shares of Class A common stock at $24.77 per share, which is recorded as a tax-withholding disposition rather than an open-market sale. Following these transactions, Dudum held 1,310,617 Class A shares directly, and also reported additional indirect holdings through several family trusts, including positions such as 3,004,071 shares held by the Trustee of the Dudum Family 2021 Trust and 2,214,769 shares held by the Trustee of the Dudum Family Heritage Trust UAD 8-10-2021.
Hims & Hers Health, Inc. Chief Legal Officer Soleil Boughton reported routine equity compensation activity involving restricted stock units (RSUs) on March 13, 2026. Multiple RSU awards covering a total of 41,421 units were exercised or converted, each RSU representing one share of Class A common stock.
To cover tax withholding obligations tied to the vesting and settlement of these RSUs, the issuer withheld 168,750 shares of Class A common stock at a price of $24.77 per share, classified as tax-withholding dispositions rather than market sales. Following these transactions, Boughton directly holds 313,643 shares of Class A common stock.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe reported equity compensation activity involving restricted stock units and Class A Common Stock. On March 13, 2026, RSUs converted into 105,200 shares of Class A Common Stock as they vested under multi‑year service-based schedules.
To cover tax withholding obligations tied to vested performance RSUs and other RSUs, the issuer withheld a total of 283,990 shares of Class A Common Stock at $24.77 per share, characterized as tax-withholding dispositions rather than market sales. Following these transactions, Okupe directly held 323,517 Class A Common shares and indirectly held 7,853 shares through the Oluyemi Okupe Separate Property Trust dated September 1, 2021.
Becklund Irene reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. reported that PAO Irene Becklund received a grant of 62,076 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Class A Common Stock. These RSUs vest over four years in substantially equal quarterly installments on March 15, June 15, September 15 and December 15, beginning on June 15, 2026, subject to continued service. Following this award, Becklund holds rights relating to 62,076 underlying shares of Class A Common Stock, reflecting a compensation-related equity grant rather than any open-market stock purchase or sale.
Chi Michael reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. reported that Chief Operating Officer Michael Chi received a grant of 376,222 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Class A common stock, making this a stock-based compensation award rather than a market purchase.
The RSUs are subject to a service-based vesting schedule over four years, vesting in substantially equal quarterly installments on March 15, June 15, September 15 and December 15, with the first vesting date on June 15, 2026. Following this grant, Chi holds 376,222 RSUs directly.
Autor Deborah M. reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. reported that Chief Policy Officer Deborah M. Autor received a grant of 526,711 Restricted Stock Units (RSUs), each representing a right to receive one share of Class A common stock. The RSUs vest over four years in substantially equal quarterly installments on March 15, June 15, September 15 and December 15, beginning on March 15, 2026. Following this award, she holds 526,711 RSUs directly.
Carroll Patrick Harrison reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. reported that Chief Medical Officer Patrick Harrison Carroll received a grant of 150,489 Restricted Stock Units. Each RSU represents a contingent right to one share of Class A Common Stock. The award vests over four years in substantially equal quarterly installments on March 15, June 15, September 15 and December 15, beginning on June 15, 2026, subject to continued service.
Boughton Soleil reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. reported that Chief Legal Officer Soleil Boughton received a grant of 188,111 Restricted Stock Units (RSUs), each representing a right to one share of Class A common stock. The RSUs vest over four years in substantially equal quarterly installments, beginning on June 15, 2026, with vesting dates on March 15, June 15, September 15 and December 15.
Elshenawy Mohamed reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. reported that CTO Mohamed Elshenawy received a grant of 376,222 Restricted Stock Units, each representing a contingent right to receive one share of Class A Common Stock. This compensation award was recorded at a price of $0.00 per unit.
The RSUs are subject to a service-based vesting schedule over four years, vesting in substantially equal quarterly installments on March 15, June 15, September 15 and December 15. The first vesting date is June 15, 2026, and continued service is required for vesting. After this grant, Elshenawy’s reported derivative holdings total 376,222 RSUs.
Dudum Andrew reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. Chief Executive Officer Andrew Dudum received a grant of 413,844 Restricted Stock Units. Each RSU represents a contingent right to receive one share of Class A common stock, so the award ties his compensation directly to future share value.
The RSUs vest over four years in substantially equal quarterly installments on March 15, June 15, September 15, and December 15, starting on June 15, 2026. Shares are delivered only as units vest, encouraging long-term service and alignment with shareholders rather than reflecting an open-market purchase.
Okupe Oluyemi reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. reported that Chief Financial Officer Oluyemi Okupe received a grant of 300,978 Restricted Stock Units (RSUs), each representing a contingent right to one share of Class A common stock.
The RSUs are subject to a service-based vesting schedule over four years. They vest in substantially equal quarterly installments on March 15, June 15, September 15 and December 15, with the first vesting date on June 15, 2026, as long as the service condition is met.
Hims & Hers Health, Inc. Chief Legal Officer Boughton Soleil sold 4,651 shares of Class A common stock in an open-market transaction. The shares were sold at an average price of $15.21 per share. After this sale, Soleil continues to hold 440,972 shares directly. The transaction was carried out under a pre-established Rule 10b5-1 trading plan adopted on November 18, 2025, indicating it was scheduled in advance rather than decided at the time of sale.
Hims & Hers Health, Inc. reported that Chief Financial Officer Oluyemi Okupe acquired 410,690 shares of Class A common stock through earned performance-based restricted stock units. The Compensation Committee certified the performance goals on February 23, 2026, and the related shares are scheduled to be delivered around March 15, 2026.
Hims & Hers Health, Inc. reported that Chief Legal Officer Boughton Soleil acquired 273,794 shares of Class A common stock through a performance-based restricted stock unit (PRSU) award. The award carried a price of $0.00 per share and lifted Soleil’s directly held stake to 445,623 shares.
The PRSUs were earned under a previously granted award after the Compensation Committee certified that the performance criteria were met as of February 23, 2026. Under the award terms, the underlying shares are scheduled to be delivered to Soleil on or about March 15, 2026.
Hims & Hers Health, Inc. Chief Operating Officer Michael Chi reported acquiring 365,058 shares of Class A common stock through earned performance-based restricted stock units (PRSUs). These PRSUs were previously granted and each unit represents the right to receive one share.
The Compensation Committee certified that the award's performance criteria were met as of February 23, 2026, and the shares are scheduled to be delivered to Chi on or about March 15, 2026. Following this grant, his direct holdings total 670,219 shares of Class A common stock.
Hims & Hers Health, Inc. reported that Chief Executive Officer Andrew Dudum acquired 794,002 shares of Class A common stock through the earning of performance-based restricted stock units (PRSUs). The award carried a grant price of $0.00 per share, reflecting a stock-based compensation grant rather than an open-market purchase.
These PRSUs were earned after the Compensation Committee certified that the performance criteria for the award were met as of February 23, 2026. Each PRSU converts into one share of Class A common stock, and the shares are scheduled to be delivered to Dudum on or about March 15, 2026. Following this acquisition, he directly holds 1,672,734 Class A shares, alongside additional indirect holdings through various family and estate planning trusts.
Hims & Hers Health, Inc.’s Chief Financial Officer, Oluyemi Okupe, reported an option exercise and share sale in Class A Common Stock on February 3, 2026.
He exercised 5,262 stock options at an exercise price of $5.01 per share, then sold 5,262 shares of Class A Common Stock at an average price of $26.4363 per share under a Rule 10b5-1 trading plan adopted on May 21, 2025. After these transactions, he directly owned 91,617 shares of Class A Common Stock and 144,051 stock options, and indirectly held 7,853 shares through the Oluyemi Okupe Separate Property Trust dated September 1, 2021.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe reported stock option exercises and a share sale. On January 20, 2026, the CFO exercised stock options for 7,317 Class A Common shares at an exercise price of $5.01 per share and for 1,750 shares at $11.53 per share. That same day, 9,067 Class A Common shares were sold at a weighted average price of $30.3423, with actual sale prices ranging from $30.21 to $30.44.
After these transactions, the CFO directly owned 91,617 Class A Common shares and held stock options covering 149,313 and 42,996 shares in two separate option awards. An additional 7,853 shares were held indirectly through the Oluyemi Okupe Separate Property Trust dated September 1, 2021. The filing states that the option exercises and related sales were carried out under a Rule 10b5-1 trading plan adopted on May 21, 2025, which is a pre-arranged program for trading company stock.
Hims & Hers Health Chief Financial Officer Oluyemi Okupe reported option exercises and a stock sale involving Class A common stock. On January 5, 2026, Okupe exercised stock options for 2,178 shares at $5.01 and 3,808 shares at $11.53 per share, receiving the same number of Class A shares. On the same day, Okupe sold 9,070 shares of Class A common stock at an average price of $33.7875.
The filing states that these option exercises and sales were carried out under a Rule 10b5-1 trading plan adopted on May 21, 2025. After the reported transactions, Okupe directly held 91,617 Class A shares and indirectly held 7,853 additional shares through the Oluyemi Okupe Separate Property Trust dated September 1, 2021.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe reported a sale of Class A common stock. On 12/22/2025, the reporting person sold 23,090 shares at an average price of $35.7172, with trades executed in a price range of $35.36–$35.88. The filing states these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on May 21, 2025, which is designed to systematically execute trades over time.
After this transaction, the reporting person beneficially owns 94,333 shares of Class A common stock directly and 7,853 shares indirectly through the Oluyemi Okupe Separate Property Trust dated 9-1-2021.
Hims & Hers Health, Inc. Chief Operating Officer Michael Chi reported selling 13,750 shares of Class A common stock on 12/17/2025 at $36.71 per share. The transaction was reported with transaction code "S" and was effected under a Rule 10b5-1 trading plan adopted on March 4, 2025.
After this sale, Chi beneficially owns 305,161 shares of Hims & Hers Health, Inc. common stock in direct ownership.
Hims & Hers Health, Inc. director and Chief Policy Officer Deborah M Autor reported selling 7,054 shares of Class A common stock on December 17, 2025 at $36.71 per share. The transaction was filed on Form 4 as a sale of non-derivative securities.
After this sale, she beneficially owned 6,175 shares of Class A common stock, held directly. The filing notes that the sale was effected under a Rule 10b5-1 trading plan adopted on August 11, 2025, indicating the trades followed a pre-established plan.
Hims & Hers Health, Inc. director and Chief Medical Officer Patrick Harrison Carroll reported selling 10,021 shares of Class A common stock on 12/17/2025 at $36.71 per share.
After this transaction, Carroll beneficially owns 169,940 shares of Hims & Hers Class A common stock, held directly. The sale was carried out pursuant to a Rule 10b5-1 trading plan adopted on May 19, 2025.
Hims & Hers Health, Inc. officer Irene Becklund reported selling 8,411 shares of Class A common stock on 12/17/2025 at $36.71 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 7, 2024. After this transaction, she directly holds 2,126 shares of Hims & Hers Health stock.
Hims & Hers Health, Inc. reported an insider equity transaction by Chief Legal Officer Soleil Boughton. On December 15, 2025, restricted stock units (RSUs) converted into 41,421 shares of Class A common stock. To cover tax withholding obligations from this vesting, the company withheld 22,817 Class A shares at $36.25 per share, after which Boughton directly owned 171,829 Class A shares.
The reported RSUs each represent a contingent right to receive one share of Class A common stock. Several RSU grants are subject to service-based vesting over four years, in substantially equal quarterly installments on Company Quarterly Vesting Dates, with first vesting dates beginning on June 15, 2022, June 15, 2023, June 15, 2024, and June 15, 2025.
Hims & Hers Health, Inc. director and Chief Medical Officer Patrick Harrison Carroll reported equity compensation activity dated December 15, 2025. Restricted stock units (RSUs) converted into 16,521 shares of Class A common stock (transaction code M), increasing his direct holdings to 186,461 shares before tax withholding.
The issuer then withheld 6,500 shares at $36.25 per share (transaction code F) to satisfy tax withholding obligations tied to the RSU vesting, leaving Carroll with 179,961 directly held shares. The RSUs vest over four-year service periods: one grant vests 25% on December 15, 2023 with the remainder in substantially equal quarterly installments on March 15, June 15, September 15 and December 15, and additional grants vest quarterly on these same Company Quarterly Vesting Dates starting June 15, 2024 and June 15, 2025.